Outcomes	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
time	B-PrimaryOutcome
to	I-PrimaryOutcome
clinical	I-PrimaryOutcome
improvement	I-PrimaryOutcome
,	O
defined	O
as	O
the	O
time	B-OutcomeDefinition
from	I-OutcomeDefinition
randomization	I-OutcomeDefinition
(	I-OutcomeDefinition
D0	I-OutcomeDefinition
)	I-OutcomeDefinition
to	I-OutcomeDefinition
an	I-OutcomeDefinition
improvement	I-OutcomeDefinition
of	I-OutcomeDefinition
2	I-OutcomeDefinition
points	I-OutcomeDefinition
on	I-OutcomeDefinition
a	I-OutcomeDefinition
7	I-OutcomeDefinition
-	I-OutcomeDefinition
category	I-OutcomeDefinition
ordinal	I-OutcomeDefinition
scale	I-OutcomeDefinition
or	I-OutcomeDefinition
live	I-OutcomeDefinition
discharge	I-OutcomeDefinition
from	I-OutcomeDefinition
the	I-OutcomeDefinition
hospital	I-OutcomeDefinition
(	I-OutcomeDefinition
Dend	I-OutcomeDefinition
)	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
improvement	I-OutcomeDefinition
rate	I-OutcomeDefinition
of	I-OutcomeDefinition
follow	I-OutcomeDefinition
-	I-OutcomeDefinition
up	I-OutcomeDefinition
CT	I-OutcomeDefinition
scans	I-OutcomeDefinition
at	B-TimeFrame
D14	I-TimeFrame
.	O

The	O
7	O
-	O
category	O
ordinal	O
scale	O
has	O
been	O
used	O
in	O
other	O
COVID	O
-	O
19	O
randomized	O
controlled	O
trials31	O
and	O
also	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
R	O
&	O
D	O
Blueprint	O
expert	O
group32	O
(	O
see	O
this	O
article	O
’	O
s	O
Methods	O
section	O
in	O
the	O
Online	O
Repository	O
)	O
.	O

Other	O
clinical	O
outcomes	O
included	O
clinical	B-OtherOutcome
improvement	I-OtherOutcome
rate	I-OtherOutcome
as	B-OutcomeDefinition
assessed	I-OutcomeDefinition
with	I-OutcomeDefinition
the	I-OutcomeDefinition
7	I-OutcomeDefinition
-	I-OutcomeDefinition
category	I-OutcomeDefinition
ordinal	I-OutcomeDefinition
scale	I-OutcomeDefinition
on	B-TimeFrame
D7	I-TimeFrame
,	I-TimeFrame
D14	I-TimeFrame
,	I-TimeFrame
D21	I-TimeFrame
,	I-TimeFrame
and	I-TimeFrame
D28	I-TimeFrame
,	O
time	B-OtherOutcome
from	I-OtherOutcome
randomization	I-OtherOutcome
to	I-OtherOutcome
lymphocyte	I-OtherOutcome
recovery	I-OtherOutcome
and	I-OtherOutcome
to	I-OtherOutcome
invasive	I-OtherOutcome
mechanical	I-OtherOutcome
ventilation	I-OtherOutcome
,	O
the	O
duration	B-OtherOutcome
of	I-OtherOutcome
hospitalization	I-OtherOutcome
in	I-OtherOutcome
survivors	I-OtherOutcome
,	O
and	O
the	O
time	B-OtherOutcome
from	I-OtherOutcome
treatment	I-OtherOutcome
initiation	I-OtherOutcome
to	I-OtherOutcome
death	I-OtherOutcome
and	O
virus	B-OtherOutcome
clearance	I-OtherOutcome
time	I-OtherOutcome
.	O

The	O
primary	O
safety	O
end	O
point	O
was	O
the	O
incidence	B-PrimaryOutcome
of	I-PrimaryOutcome
serious	I-PrimaryOutcome
adverse	I-PrimaryOutcome
events	I-PrimaryOutcome
occurring	O
up	B-TimeFrame
to	I-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
.	O

Safety	O
outcomes	O
included	O
adverse	O
events	O
and	O
serious	B-OtherOutcome
adverse	I-OtherOutcome
events	I-OtherOutcome
that	O
occurred	O
during	O
treatment	O
.	O

Particularly	O
,	O
the	O
eventual	O
negative	B-OtherOutcome
impact	I-OtherOutcome
of	I-OtherOutcome
ruxolitinib	I-OtherOutcome
on	I-OtherOutcome
SARS	I-OtherOutcome
-	I-OtherOutcome
CoV	I-OtherOutcome
-	I-OtherOutcome
2	I-OtherOutcome
virus	I-OtherOutcome
clearance	I-OtherOutcome
and	O
its	O
specific	O
IgM	B-OtherOutcome
and	I-OtherOutcome
/	I-OtherOutcome
or	I-OtherOutcome
IgG	I-OtherOutcome
-	I-OtherOutcome
antibody	I-OtherOutcome
formation	I-OtherOutcome
and	O
/	O
or	O
lymphocyte	B-OtherOutcome
recovery	I-OtherOutcome
was	O
also	O
included	O
in	O
the	O
safety	O
profile	O
.	O

Lymphopenia	O
was	O
defined	O
as	O
peripheral	O
absolute	O
lymphocytes	O
less	O
than	O
1	O
.	O
0	O
×	O
109	O
/	O
L	O
.	O

Lymphocyte	O
recovery	O
time	O
was	O
defined	O
as	O
the	B-OutcomeDefinition
first	I-OutcomeDefinition
day	I-OutcomeDefinition
at	I-OutcomeDefinition
which	I-OutcomeDefinition
lymphocytes	I-OutcomeDefinition
returned	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
normal	I-OutcomeDefinition
levels	I-OutcomeDefinition
within	I-OutcomeDefinition
the	I-OutcomeDefinition
observation	I-OutcomeDefinition
period	I-OutcomeDefinition
.	O

The	O
virus	O
clearance	O
time	O
was	O
defined	O
as	O
the	B-OutcomeDefinition
time	I-OutcomeDefinition
from	I-OutcomeDefinition
randomization	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
first	I-OutcomeDefinition
day	I-OutcomeDefinition
of	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
2	I-OutcomeDefinition
consecutive	I-OutcomeDefinition
negative	I-OutcomeDefinition
RT	I-OutcomeDefinition
-	I-OutcomeDefinition
PCR	I-OutcomeDefinition
assays	I-OutcomeDefinition
separated	I-OutcomeDefinition
by	I-OutcomeDefinition
24	I-OutcomeDefinition
hours	I-OutcomeDefinition
apart	I-OutcomeDefinition
.	I-OutcomeDefinition

The	O
secondary	O
end	O
point	O
is	O
the	O
overall	B-SecondaryOutcome
mortality	I-SecondaryOutcome
at	B-TimeFrame
D28	I-TimeFrame
.	O

The	O
investigational	O
outcomes	O
included	O
the	O
dynamic	B-OtherOutcome
changes	I-OtherOutcome
in	I-OtherOutcome
the	I-OtherOutcome
virus	I-OtherOutcome
copies	I-OtherOutcome
,	O
cytokine	B-OtherOutcome
profile	I-OtherOutcome
,	O
SARS	B-OtherOutcome
-	I-OtherOutcome
CoV	I-OtherOutcome
-	I-OtherOutcome
2	I-OtherOutcome
–	I-OtherOutcome
speicific	I-OtherOutcome
antibody	I-OtherOutcome
,	O
and	O
its	O
correlation	B-OtherOutcome
with	I-OtherOutcome
clinical	I-OtherOutcome
treatment	I-OtherOutcome
response	I-OtherOutcome
.	O

